HIGH BLOOD SUGAR; COVID-19; This spontaneous case was reported by a consumer and describes the occurrence of BLOOD GLUCOSE INCREASED (HIGH BLOOD SUGAR) in a 56-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Crohn's disease.    No other Medical History information was reported.    On 01-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. In December 2021, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) UNK Citrate Free. On 01-Jan-2022, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced BLOOD GLUCOSE INCREASED (HIGH BLOOD SUGAR) (seriousness criterion hospitalization) and COVID-19 (COVID-19). At the time of the report, BLOOD GLUCOSE INCREASED (HIGH BLOOD SUGAR) had resolved and COVID-19 (COVID-19) outcome was unknown.            No concomitant products were reported.  on an unknown date, the patient experienced high blood sugar. In 2022, the patient experienced covid. on an unknown date, high blood sugar resolved. Moderna covid-19 vaccine (elasomeran) was also considered suspect. The patient was hospitalized due to sugar over 700. she was off humira since dec  2021. She started to felt difference since off humira and it was better. She had covid after first booster and only lost taste. It was she if patient was enrolled in a covid-19 vaccine trial.   The reporter's causality for the event(s) of high blood sugar and covid was not provided. There was no reasonable possibility that the events of high blood sugar and covid are related to humira (adalimumab).  No treatment information was reported by the reporter.  This case was identified as part of a retrospective clean-up activity where certain emails received in the moderna mailbox were missed to be booked-in.  Company comment: This is a spontaneous case reported by a consumer. A 56-year-old female patient, in treatment with Adalimumab for Crohn's disease, received 3 doses of mRNA-1273 vaccine and experienced serious event of blood glucose increased. Onset date of the event was not provided; hence, latency cannot be assessed. The patient was hospitalized due to sugar over 700. Additionally, patient experienced non serious event of COVID-19 (AESI) after first booster and only lost taste.  No further details regarding clinical course, diagnostic tests or treatment performed were disclosed. Concurrent medical condition of Crohn's disease could be a contributory factor for the events. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.   This case was linked to MOD-2022-595930 (Patient Link).; Sender's Comments: This is a spontaneous case reported by a consumer. A 56-year-old female patient, in treatment with Adalimumab for Crohn's disease, received 3 doses of mRNA-1273 vaccine and experienced serious event of blood glucose increased. Onset date of the event was not provided; hence, latency cannot be assessed. The patient was hospitalized due to sugar over 700. Additionally, patient experienced non serious event of COVID-19 (AESI) after first booster and only lost taste.  No further details regarding clinical course, diagnostic tests or treatment performed were disclosed. Concurrent medical condition of Crohn's disease could be a contributory factor for the events. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.